A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind phase2 study to evaluate the safety and
investigate the efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of Hemay007 in
Patients with moderate to severe Rheumatoid Arthritis who are on a stable dose of DMARDs.